Genome-wide association study of prostate cancer-specific survival.

نویسندگان

  • Robert Szulkin
  • Robert Karlsson
  • Thomas Whitington
  • Markus Aly
  • Henrik Gronberg
  • Rosalind A Eeles
  • Douglas F Easton
  • Zsofia Kote-Jarai
  • Ali Amin Al Olama
  • Sara Benlloch
  • Kenneth Muir
  • Graham G Giles
  • Melissa C Southey
  • Liesel M FitzGerald
  • Brian E Henderson
  • Fredrick R Schumacher
  • Christopher A Haiman
  • Csilla Sipeky
  • Teuvo L J Tammela
  • Børge G Nordestgaard
  • Timothy J Key
  • Ruth C Travis
  • David E Neal
  • Jenny L Donovan
  • Freddie C Hamdy
  • Paul D P Pharoah
  • Nora Pashayan
  • Kay-Tee Khaw
  • Janet L Stanford
  • Stephen N Thibodeau
  • Shannon K McDonnell
  • Daniel J Schaid
  • Christiane Maier
  • Walther Vogel
  • Manuel Luedeke
  • Kathleen Herkommer
  • Adam S Kibel
  • Cezary Cybulski
  • Jan Lubiński
  • Wojciech Kluźniak
  • Lisa Cannon-Albright
  • Hermann Brenner
  • Volker Herrmann
  • Bernd Holleczek
  • Jong Y Park
  • Thomas A Sellers
  • Hui-Yi Lim
  • Chavdar Slavov
  • Radka P Kaneva
  • Vanio I Mitev
  • Amanda Spurdle
  • Manuel R Teixeira
  • Paula Paulo
  • Sofia Maia
  • Hardev Pandha
  • Agnieszka Michael
  • Andrzej Kierzek
  • Jyotsna Batra
  • Judith A Clements
  • Demetrius Albanes
  • Gerald L Andriole
  • Sonja I Berndt
  • Stephen Chanock
  • Susan M Gapstur
  • Edward L Giovannucci
  • David J Hunter
  • Peter Kraft
  • Loic Le Marchand
  • Jing Ma
  • Alison M Mondul
  • Kathryn L Penney
  • Meir J Stampfer
  • Victoria L Stevens
  • Stephanie J Weinstein
  • Antonia Trichopoulou
  • Bas H Bueno-de-Mesquita
  • Anne Tjønneland
  • David G Cox
  • Lovise Maehle
  • Johanna Schleutker
  • Sara Lindström
  • Fredrik Wiklund
چکیده

BACKGROUND Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical. METHODS We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR). RESULTS We observed no significant association between genetic variants and prostate cancer survival. CONCLUSIONS Common genetic variants with large impact on prostate cancer survival were not observed in this study. IMPACT Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Association between prostate specific antigen change over time and prostate cancer recurrence risk: a joint model

Background: Prostate specific antigen (PSA) is an important biomarker to monitor patients after treated with radiation therapy (RT). The aim of this study is to evaluate the relationship between the PSA data and prostate cancer recurrence using the joint modeling. Methods: This historical cohort study was performed on 422 prostate cancer patients. Inclusion criteria included: patients with loc...

متن کامل

Association between rs2735839 and Serum Prostate-specific Antigen Level Regarding Risk of Prostate Cancer in Iranian Population

Background and Objective: Prostate cancer is among the five common cancers in males. It is second cancer in terms of the age-standardized rate (ASR) (ASR=16.6) in Iran. The rs2735839 G/A, an intergenic polymorphism is located on chromosome 19q13.33 at 600 base pairs of the KLK3 gene untranslatable region. This gene which codes prostate-specific antigen (PSA) is used in the screening and diagnos...

متن کامل

Association Study of miR-124-a-3 Gene rs34059726 Polymorphism with Prostate Cancer in Gonbad Kavous

Background: MiRNAs are one of the most important genetic regulators that regulate more than 50 percent of the human genome. MiR-124-a-3 is a tumor suppressor miRNA which its expression dramatically reduced in prostate cancer tumor cells. Since miRNA binding to the transcript of target genes by seed sequence, any mutations and changes in this region could be effective on its performance and iden...

متن کامل

Prostate-specific antigen kinetics after hypofractionated stereotactic body radiotherapy for localized prostate cancer

Background: stereotactic body radiotherapy (SBRT) has emerged as an effective treatment for localized prostate cancer. However, prostate-specific antigen (PSA) kinetics after SBRT has not been well characterized. The objective of the current study is to analyze the rate of PSA decline and PSA nadir following hypofractonated SBRT in localized prostate cancer. Materials and Methods: From 2008...

متن کامل

PSA Screening in Prostate Cancer

Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

دوره 24 11  شماره 

صفحات  -

تاریخ انتشار 2015